Promising Avextra Study Results Unveiled at Pain Congress
Avextra Pharma’s cannabis-based medicine, Avextra 10/10 (a 1:1 THC/CBD extract), demonstrated superior efficacy and tolerability in treating chemotherapy-induced neuropathic...
Atyr Pharma Publishes Efzofitimod Data in Prestigious Journal
aTyr Pharma announced a publication in Science Translational Medicine detailing the mechanism of action of efzofitimod, its lead therapeutic...
Soquelitinib in Phase 2 Trial for ALPS
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has launched a Phase 2 clinical...
Promising Avextra Pain Study Unveiled at Congress
Avextra Pharma’s cannabis-based medicine, Avextra 10/10 (a 1:1 THC/CBD extract), demonstrated superior efficacy and tolerability in treating chemotherapy-induced neuropathic...
ACTG CMV Study Shows Improved Aging in HIV/CMV Patients
The AIDS Clinical Trials Group (ACTG) presented promising phase 2 trial results at the 2025 Conference on Retroviruses and...
Bad Science Used to Support Regulations
Drs. S. Stanley Young and Warren Kindzierski explored the reproducibility crisis in scientific research, specifically how unreliable studies influence...
ACTG Presents Data from MPOX Study STOMP at CROI
The AIDS Clinical Trials Group (ACTG) presented data from the STOMP trial at the 2025 Conference on Retroviruses and...
Rakovina’s AI Cancer Treatment Enters Preclinical Trials
Rakovina Therapeutics has received its first synthesized batch of AI-generated ATR inhibitor compounds, developed in partnership with Variational AI....
CLENE CNM-Au8® Shows ALS Survival Benefit
Clene Inc. announced positive results from a new analysis of the HEALEY ALS Platform Trial data. The analysis showed...
GDPR and Cross-Border Data Transfers in Clinical Trials
Cross-border data transfers are a critical yet complex aspect in clinical trials. With global collaborations becoming the norm, personal...